Role of alendronate in therapy for postt
β
Daniel-Henri Manicourt; Jean-Pierre Brasseur; Yves Boutsen; Geneviève Depreseux;
π
Article
π
2004
π
John Wiley and Sons
π
English
β 98 KB
π 1 views
## Abstract ## Objective To evaluate the effects of the antiresorptive agent alendronate at a daily oral dose of 40 mg in patients with posttraumatic complex regional pain syndrome type I (CRPS I) of the lower extremity. ## Methods Forty patients were enrolled in this 8βweek randomized, doubleβb